Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $11.00

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has been assigned an average recommendation of "Buy" from the seven research firms that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $11.00.

Several brokerages have issued reports on AQST. Leerink Partners raised their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Cantor Fitzgerald began coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an "overweight" rating and a $17.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, December 20th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. nVerses Capital LLC bought a new position in shares of Aquestive Therapeutics in the third quarter worth $28,000. New York State Common Retirement Fund increased its position in shares of Aquestive Therapeutics by 713.3% in the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock worth $43,000 after purchasing an additional 10,700 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Aquestive Therapeutics in the fourth quarter worth $44,000. PKS Advisory Services LLC bought a new position in shares of Aquestive Therapeutics in the fourth quarter worth $63,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Aquestive Therapeutics in the fourth quarter worth $69,000. Institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock traded down $0.15 during mid-day trading on Friday, hitting $3.32. 1,531,790 shares of the company's stock traded hands, compared to its average volume of 1,180,782. The firm has a 50 day simple moving average of $3.33 and a two-hundred day simple moving average of $4.19. Aquestive Therapeutics has a fifty-two week low of $2.24 and a fifty-two week high of $6.23. The stock has a market cap of $302.72 million, a price-to-earnings ratio of -7.38 and a beta of 2.67.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.